 - Patients must have BRAFV600E or BRAFV600K mutations, identified by a Food and Drug Administration FDA-approved test at a Clinical Laboratory Improvement Amendments CLIA-certified laboratory lab; if test at CLIA-certified lab used a non-FDA approved method, information about the assay must be provided 